Advertisement

Impact of Institutional Universal Microsatellite-Instability (MSI) Reflex Testing on Molecular Profiling Differences Between Younger and Older Patients with Colorectal Cancer

Published:September 29, 2022DOI:https://doi.org/10.1016/j.clcc.2022.09.004

      Abstract

      Introduction

      DNA mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) colorectal cancer (CRC) is found in about 15% of early-stage diseases and 5% of metastatic diseases. We reviewed a large, single-institutional database after implementation of universal reflex dMMR/MSI-H testing in CRC to compare profiles of younger (≤50) and older (>50) patients.

      Patients and Methods

      Between 2009 and 2017, all patients diagnosed with CRC at the University of Florida underwent reflex somatic tumor testing for dMMR by immunohistochemistry (MLH1, PMS2, MSH2, MSH6), MSI by PCR, and Next-Generation Sequencing. Statistical analysis was conducted with 2-sample comparison tests and logistic regression models.

      Results

      There were 375 patients included in the final analysis. Patients were grouped as younger (ages ≤50 years-old; n = 80) or older (>50 years-old; n = 295). Compared to tumors from older patients, tumors from younger patients were less likely to be dMMR/MSI-H (12.5% vs. 21.4%, P = .013) and less likely to have a BRAF mutation (1.5% vs. 16.1%, P = .002). BRAF mutation status was highly associated with MMR status; BRAF-mutated tumors were 29.7 times more likely than BRAF-WT tumors to be dMMR/MSI-H (P = < .001, 95% CI 11.3-78.3).

      Conclusions

      Tumors of younger patients were less likely than tumors of older patients to have a dMMR/MSI-H or BRAF mutation. Universal MMR/MSI testing in our dataset identified a relatively large population of older patients with sporadic CRC who were eligible for immunotherapy.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Colorectal Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Siegel RL
        • Miller KD
        • Jemal A.
        Cancer statistics.
        CA: Cancer J Clin. 2018; 68 (2018): 7-30https://doi.org/10.3322/caac.21442
        • Virostko J
        • Capasso A
        • Yankeelov TE
        • Goodgame B.
        Recent trends in the age at diagnosis of colorectal cancer in the US National Cancer Data Base, 2004-2015.
        Cancer. 2019; 125: 3828-3835https://doi.org/10.1002/cncr.32347
        • US Preventive Services Task Force
        Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement.
        JAMA. 2021; 325: 1965-1977https://doi.org/10.1001/jama.2021.6238
        • Peltomaki P.
        Role of DNA mismatch repair defects in the pathogenesis of human cancer.
        J Clin Oncol. 2003; 21: 1174-1179https://doi.org/10.1200/JCO.2003.04.060
      1. Benson AB, Venook AP, Al-Hawary MM. NCCN Guidelines for Colon Cancer. Version 2.2018. doi: 10.6004/jnccn.2018.0021.

        • Sargent DJ
        • Marsoni S
        • Monges G
        • et al.
        Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer.
        J Clin Oncol. 2010; 28: 3219https://doi.org/10.1200/JCO.2009.27.1825
      2. Overman MJ, McDermott R, Leach JL, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol 2017;18(9):1182-91. doi: 10.1016/S1470-2045(17)30422-9.

        • Le DT
        • Durham JN
        • Smith KN
        • et al.
        Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.
        Science. 2017; 357: 409-413https://doi.org/10.1126/science.aan6733
        • Overman MJ
        • Lonardi S
        • Wong KYM
        • et al.
        Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer.
        J Clin Oncol. 2018; 36: 773-779https://doi.org/10.1200/JCO.2017.76.9901
        • Haraldsdottir S
        • Roth R
        • Pearlman R
        • Hampel H
        • Arnold CA
        • Frankel WL.
        Mismatch repair deficiency concordance between primary colorectal cancer and corresponding metastasis.
        Familial Cancer. 2016; 15: 253-260https://doi.org/10.1007/s10689-015-9856-2
        • Gallego CJ
        • Shirts BH
        • Bennette CS
        • et al.
        Next-generation sequencing panels for the diagnosis of colorectal cancer and polyposis syndromes: a cost-effectiveness analysis.
        J Clin Oncol. 2015; 33: 2084https://doi.org/10.1200/JCO.2014.59.3665
        • Bakry D
        • Aronson M
        • Durno C
        • et al.
        Genetic and clinical determinants of constitutional mismatch repair deficiency syndrome: report from the constitutional mismatch repair deficiency consortium.
        Eur J Cancer. 2014; 50: 987-996https://doi.org/10.1016/j.ejca.2013.12.005
        • Sepulveda AR
        • Hamilton SR
        • Allegra CJ
        • et al.
        Molecular biomarkers for the evaluation of colorectal cancer: guideline from the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology.
        Am J Clin Pathol. 2017; 147: 221-260https://doi.org/10.1200/JCO.2016.71.9807
        • Li P
        • Xiao Z
        • Braciak TA
        • Ou Q
        • Chen G
        • Oduncu FS
        Impact of age and mismatch repair status on survival in colorectal cancer.
        Cancer Med-us. 2017; 6: 975-981https://doi.org/10.1371/journal.pone.0172799
        • Vos JR
        • Fakkert IE
        • Liesbeth S
        • et al.
        Evaluation of yield and experiences of age-related molecular investigation for heritable and nonheritable causes of mismatch repair deficient colorectal cancer to identify Lynch syndrome.
        Int J Cancer. 2020; 147: 2150-2158https://doi.org/10.1002/ijc.33117
        • Yamada A
        • Matsuoka Y
        • Minamiguchi S
        • et al.
        Real-world outcome of universal screening for Lynch syndrome in Japanese patients with colorectal cancer highlights the importance of targeting patients with young-onset disease.
        Mol Clin Oncol. 2021; 15: 247https://doi.org/10.3892/mco.2021.2409
        • Stigliano V
        • Sanchez-Mete L
        • Martayan A
        • Anti M.
        Early-onset colorectal cancer: a sporadic or inherited disease?.
        World J Gastroenterol. 2014; 20: 12420https://doi.org/10.3748/wjg.v20.i35.12420
        • De la Fouchardière C
        • Cohen R
        • Malka D
        • et al.
        Characteristics of BRAFV600E mutant, deficient mismatch repair/proficient mismatch repair, metastatic colorectal cancer: a multicenter series of 287 patients.
        Oncologist. 2019; 24: e1331-e1340https://doi.org/10.1634/theoncologist.2018-0914
        • Brenner DR
        • Heer E
        • Sutherland RL
        • et al.
        National trends in colorectal cancer incidence among older and younger adults in Canada.
        JAMA Netw Open. 2019; 2 (e198090-e)https://doi.org/10.1001/jamanetworkopen.2019.8090